Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 36

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 36
---
 have a disproportionately
positive or negative impact on our results of operations, financial condition, prospects, and market value.

Our
current business strategy includes the possibility of entering into collaborative arrangements with third parties to complete the development
and commercialization of our drug candidates. In the event that third parties are contracted to manage the clinical trial process for
one or more of our drug candidates, the estimated completion date would largely be under the control of that third party rather than
us. We cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future collaborative
arrangements, in whole or in part, and how such arrangements would affect our development plan or capital requirements. We may also apply
for subsidies, grants or government or agency-sponsored studies that could reduce our development costs. However, we cannot forecast
with any degree of certainty whether we will be selected to receive any subsidy, grant or governmental funding.

As
of September 30, 2025, the Company had $5.3 million in cash and cash equivalents to fund its operations. The Company’s primary
sources of cash have been proceeds from the issuance and sale of its common stock, including via its at-the-market (“ATM”)
program and other potential funding transactions. There can be no assurance that the Company will be able to do so in the future on a
timely basis on terms acceptable to the Company, or at all. The Company has not yet commercialized any of its product candidates. Even
if the Company commercializes one or more of its product candidates, it may not become profitable in the near term. The Company’s
ability to achieve profitability depends on several factors, including its ability to obtain regulatory approval for its product candidates,
successfully complete any post-approval regulatory obligations and successfully commercialize its product candidates alone or in partnership.

Such
conditions raise substantial doubts about the Company’s ability to continue as a going concern. Based on the above, management
has determined there is substantial doubt regarding our ability to continue as a going concern. The report of our independent registered
public accounting firm for the year ended December 31, 2024, includes an explanatory paragraph which expresses substantial doubt about
our ability to continue as a going concern. See also Note 2 to the Condensed Consolidated Financial Statements contained in this Quarterly
Report on Form 10-Q.

Management’s
plan includes private or public equity financings, collaborations, or other strategic transactions such as raising funds from outside
investors via its ATM